Market Overview

Momenta Pharmaceuticals Falls 17% on Patent Infringement Ruling

Related MNTA
A District Court's Ruling Against Teva Pharma Opens The Door For Generics
Mid-Afternoon Market Update: Under Armour Drops On Earnings Miss; Jaguar Animal Health Shares Climb
Momenta halted after noting compliance issue in drug application (Seeking Alpha)

Momenta Pharmaceuticals (NASDAQ: MNTA) is trading lower on the session after announcing that Teva Pharmaceutical (NASDAQ: TEVA) received a favorable ruling in COPAXONE patent infringement case. The decision is subject to appeal.

Craig Wheeler, President and Chief Executive Officer of Momenta. "We are disappointed that the court determined that Teva's patents were valid and infringed, and we look forward to reading the full opinion to understand its reasoning. We remain confident in our legal position and we intend to appeal."

Momenta Pharmaceuticals is currently trading at $14.02, a loss of $2.99 or 17.61%.

Posted-In: Intraday Update Movers


Related Articles (MNTA + TEVA)

View Comments and Join the Discussion!